股东名称持股比例认缴出资额认缴出资日期首次持股日期海森生物医药（香港）控股有限公司 100%352331.6667万元人民币2023年9月30日 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 受理号JTS2600031药品名称莱达西贝普注射液药品类型申请类型进口注册分类生物制品企业名称PCI San Diego;LIB Therapeutics, Inc.;海森生物医药有限公司;承办日期2026年2月28日 天眼查数据显示，海森生物医药有限公司成立日期2020年09月16日，法定代表人刘文军，所属行业为化 学药品原料药制造，企业类型为有限责任公司(港澳台法人独资)，企业规模为小型，参保人数49，注册 资本352331.6667万人民币，实缴资本352331.6667万人民币，注册地址为安徽省合肥市肥东县店埠镇山 水路99号。股东信息如下： 来源：新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示，2026年2月28日，PC ...

来源：新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示，2026年2月26日，宜昌东阳光长江药业股份有限公司的艾 拉莫德片申请已获受理，受理号为CYHS2600536。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 受理号CYHS2600536药品名称艾拉莫德片药品类型化药申请类型仿制注册分类4企业名称宜昌东阳光长 江药业股份有限公司;宜昌东阳光长江药业股份有限公司;承办日期2026年2月26日 天眼查数据显示，宜昌东阳光长江药业股份有限公司成立日期2001年08月08日，法定代表人唐新发，所 属行业为化学药品原料药制造，企业类型为股份有限公司(台港澳与境内合资、上市)，企业规模为大 型，参保人数4093，注册资本87996.77万人民币，实缴资本45082.285万人民币，注册地址为湖北省宜昌 宜都市滨江路38号。股东信息如下： 股东名称持股比例认缴出资额认缴出资日期首次持股日期广东东阳光药业股份有限公司 25.71% ...

受理号CYHB2600219药品名称丙戊酸钠口服溶液药品类型化药申请类型补充申请注册分类企业名称赛 诺菲（杭州）制药有限公司;赛诺菲（杭州）制药有限公司;承办日期2026年2月4日 来源：新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示，2026年2月4日，赛诺菲（杭州）制药有限公司的丙戊酸钠 口服溶液申请已获受理，受理号为CYHB2600219。 股东名称持股比例认缴出资额认缴出资日期首次持股日期法国赛诺菲药业发展公司75%2160万美元2023 年12月31日2006年10月26日赛诺菲（中国）投资有限公司25%720万美元2023年12月31日2007年05月08 日 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 天眼查数据显示，赛诺菲（杭州）制药有限公司成立日期1995年11月30日，法定代表人孙博弘，所属行 业为化学药品原料药制造，企业类型为有限责任公司（外商投资、非独资），企业规模为中型，参保人 数498，注 ...

Group 1 - On December 25, 2023, the company disclosed that its subsidiary, Ningxia Senxuan, was fined 500,000 yuan due to environmental pollution issues [2] - The pollution incident occurred when a frozen wastewater discharge pipe led to the illegal disposal of approximately 150 tons of untreated wastewater, resulting in environmental contamination [2] - The court sentenced Ningxia Senxuan for environmental pollution, imposing a fine of 500,000 yuan, while the responsible safety and environmental head received a prison sentence of 2 years and 6 months, with a 3-year probation [2] Group 2 - The company holds a 51% stake in Ningxia Senxuan, which reported an audited revenue of 32.14 million yuan and a net loss of 11.44 million yuan in its latest financial period [3] - Ningxia Senxuan's revenue and net loss accounted for 5.98% and 9.25% of the company's consolidated revenue and net profit attributable to shareholders, respectively [3] - Following the incident, the company took corrective actions and resumed normal operations by July 2024, with a reported revenue of 411 million yuan and a net profit of 104 million yuan for the first three quarters of 2025 [3]

Investment Rating - The report assigns an "Accumulate" rating for the company [1] Core Views - The company is a leading player in the sulfonamide raw material drug industry, with a comprehensive product chain and competitive advantages. It has achieved significant revenue and net profit growth in the first three quarters of 2025, with revenue reaching 164 million yuan, a year-on-year increase of 40.89%, and net profit attributable to shareholders of 49.05 million yuan, up 47.16% year-on-year [3][49] - The company has established strong barriers to entry in the market through its technical capabilities and stable customer relationships, allowing it to expand into high-value human pharmaceutical raw materials [4][30] - The regulatory environment is improving, which is expected to enhance the competitive landscape, with the company being less affected by the "antibiotic ban" and "reduction" policies [5] Summary by Sections Company Overview - The company focuses on the research, production, and sales of veterinary and pharmaceutical raw materials and intermediates, recognized as one of the most competitive enterprises in the sulfonamide raw material drug sector [3][14] - It has been designated as a national high-tech enterprise since 2016, maintaining its status through continuous innovation and quality control [3][23] Financial Performance - In the first three quarters of 2025, the company reported a revenue of 164 million yuan, a 40.89% increase year-on-year, and a net profit of 49.05 million yuan, reflecting a 47.16% growth [49] - The projected net profits for 2025-2027 are estimated at 66 million, 76 million, and 87 million yuan, respectively, with corresponding EPS of 0.66, 0.76, and 0.87 yuan per share [3] Market Position and Competitive Advantage - The company has a deep customer resource barrier, with long-term stable relationships with major clients, which enhances its pricing power and profit margins [30] - It has received multiple certifications for its products, including approvals from the National Medical Products Administration and the European Medicines Agency, which facilitate entry into high-end markets [4][34] Industry Trends - The raw material drug market in China reached 426.5 billion yuan in 2021, with a growth rate of 10.98% from 2018 [5] - The veterinary raw material drug market is showing signs of recovery, with improved supply-demand dynamics and rising prices for key products [39][41]

Core Viewpoint - The lawsuit involving Changcheng Securities is a historical issue from over 20 years ago, focusing on the confirmation of shareholder identity due to the company's operational suspension and revocation of its business license, making the valuation of its equity uncertain [1][5]. Group 1: Lawsuit Details - On September 16, Changcheng Securities announced a court hearing for a "shareholder qualification confirmation dispute" against Shenzhen Sanjiu Weitai Co., Ltd., with a hearing scheduled for November 7 [2]. - Changcheng Securities is seeking confirmation of its ownership of 900,000 shares in Sanjiu Weitai and requests the issuance of share certificates and registration in the shareholder registry [2]. Group 2: Background of Sanjiu Weitai - Sanjiu Weitai Co., established in 1993, was a chemical pharmaceutical raw material manufacturer that had its business license revoked in 2022 and is now considered a "zombie enterprise" [4]. - The company was once part of the well-known "999" brand, which has since been absorbed by China Resources Group during a restructuring process due to financial difficulties [10][11]. Group 3: Historical Context and Financial Implications - In 2008 and 2009, Changcheng Securities attempted to sell shares in 12 companies, including the 900,000 shares of Sanjiu Weitai, with the initial listing price dropping from 30,285,700 yuan to 24,228,600 yuan [7]. - The ongoing legal actions are part of a broader effort to resolve historical issues related to equity ownership, which arose during the transfer of shares by original shareholders between 2000 and 2008 [8]. Group 4: Legal and Financial Strategy - Legal experts suggest that the lawsuit serves multiple purposes: confirming shareholder identity, facilitating the appointment of a liquidation team, and ensuring rights to any remaining assets post-liquidation [8]. - For Changcheng Securities, which has total assets exceeding 100 billion yuan, resolving these historical equity issues is more about clarifying asset ownership than financial gain from the "zombie enterprise" [9].

Core Viewpoint - Changcheng Securities has initiated a lawsuit against Sanjiu Weitai Co., Ltd. to confirm its shareholder status and seek the issuance of share certificates for its 900,000 shares, as the company has been dissolved and is no longer operational [1][2]. Group 1: Company Background - Sanjiu Weitai Co., Ltd. was established in 1993 and was a manufacturer of chemical pharmaceutical raw materials, but its business license was revoked in 2022 [2]. - The company was once associated with the well-known "999" brand, which was part of the Shenzhen Southern Pharmaceutical Factory, now a residential area [2][6]. - The original Sanjiu Group, founded in 1991, expanded significantly but faced liquidity crises leading to restructuring by China Resources Group in 2007 [6][7]. Group 2: Legal Proceedings - The lawsuit is part of a historical issue dating back over 20 years, aimed at clarifying the ownership of assets and ensuring compliance as a listed company [5]. - Changcheng Securities has previously attempted to divest its shares in Sanjiu Weitai, with the shares listed for sale at a significantly reduced price in 2008 [3][4]. - The legal action may also facilitate the appointment of a liquidation team for Sanjiu Weitai, as it has not undergone liquidation since its license was revoked [4]. Group 3: Industry Context - The broader context involves the ongoing cleanup of "zombie enterprises" by state-owned enterprises, with efforts to clear out non-core and inefficient assets [7]. - China Resources Group has been actively pursuing the liquidation of former subsidiaries of the Sanjiu Group, with over 20 forced liquidation cases filed recently [7][8].

本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创业板公司具 有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成长期、经营风险高、业 绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应充分了解创业板 市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 湖北省宏源药业科技股份有限公司 Hubei Hongyuan Pharmaceutical Technology Co., Ltd. （湖北省罗田县凤山镇经济开发区宏源路 8 号） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 湖北省宏源药业科技股份有限公司 招股说明书 | 发行股票类型： | 人民币普通股（A 股） | | | | | --- | --- | --- | --- | --- | | 发行股数： | 本次股票的发行总量为 股本的比例为 | | | 4,725.72 万股，占公司发行后总 11.81%；本次发行公司原股东不公开发售 | | | 股份 | | | | | 每股面值： | 人民币 元 | | 1.00 | | | 每股发行价格： | 人 ...

安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 海国际中心 B 座 17 楼） 1-1-0 证券简称： 峆一药业 证券代码： 430478 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...

证券简称： 峆一药业 证券代码： 430478 安徽峆一药业股份有限公司 安徽省天长市杨村工业区 安徽峆一药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律 效力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 要服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面 临较大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 保荐机构（主承销商） （安徽省合肥市梅山路 18 号） 联席主承销商 （中国（四川）自由贸易试验区成都市高新区交子大道 177 号中 1-1-0 海国际中心 B 座 17 楼） 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票 ...